Combined modality treatment of laryngeal squamous cell carcinoma

References

• Jemal A, Siegel R, Ward E et al. Cancer Statistics 2006. CA Cancer J. Clin.56, 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Almadori G, Bussu F, Cadoni G et al. Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur. J. Cancer41(5), 683–693 (2005).
   PubMed Web of Science ®Google Scholar
• Spitz M. Epidemiology and risk factors for head and neck cancer. Semin. Oncol.21, 281 (1994).
   PubMed Web of Science ®Google Scholar
• Smith AH, Handley MA, Wood R. Epidemiological evidence indicates asbestos causes laryngeal cancer. J. Occup. Med.32(6), 499–507 (1990).
   PubMedGoogle Scholar
• Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J. Clin. Oncol.24(17), 2606–2611 (2006).
   PubMed Web of Science ®Google Scholar
• Forastiere A, Koch W, Trotti A et al. Head and neck cancer. N. Engl. J. Med.345, 1890–1900 (2001).
   PubMed Web of Science ®Google Scholar
• Keloff GJ, Lippman SM, Dannenberg AJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer – a plan to move forward. Clin. Cancer Res.12(12), 3661–3697 (2006).
   PubMedGoogle Scholar
• Valente G, Giusti U, Kerim S et al. High prognostic impact of growth fraction parameters in advanced stage laryngeal squamous cell carcinoma. Oncol. Rep.6(2), 289–293 (1999).
   PubMedGoogle Scholar
• Sessions RB, Harrison LB, Forasteire AA. Tumors of the larynx and hypopharynx. In: Cancer: Principles and Practice of Oncology (6th Edition). DeVita DT, Hellman S, Rosenberg SA (Eds). Lippincott Willams & Wilkins, PA, USA 860–886 (2001).
   Google Scholar
• Lee K, Strauss M. Head and neck cancer in blacks. J. Natl Med. Assoc.86, 530–534 (1994).
   PubMedGoogle Scholar
• Greene F, Page D, Fleming I et al. Larynx. In: AJCC (American Joint Committee on Cancer) Manual for Staging of Cancer (6th Edition). Springer-Verlag, NY, USA 51–62 (2002).
   Google Scholar
• Shah JP, Karnell LH, Hoffman HT et al. Patterns of care for cancer of the larynx in the United States. Arch. Otolaryngol. Head Neck Surg.123, 475–483 (1997).
   PubMedGoogle Scholar
• Nguyen TD, Malissard L, Theobald S et al. Advanced carcinoma of the larynx: results of surgery and radiotherapy without induction chemotherapy (1980–1985): a multivariate analysis. Int. J. Radiat. Oncol. Biol. Phys.36, 1013–1018 (1996).
   PubMedGoogle Scholar
• Pfister DG, Laurie SA, Weinstein GA et al. American Society of Clinical Oncology clinical practice guidelines for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J. Clin. Oncol.24(22), 3693–3704 (2006).
   PubMed Web of Science ®Google Scholar
• Gussenbauer C. Uber die erst durch T. Billroth am menschen ausgefuhrte kehlkopf extirpation. Arch. Clin. Chir.17, 343 (1872).
   Google Scholar
• Sessions DG, Lenox J, Spector GJ. Supraglottic laryngeal cancer: analysis of treatment results. Laryngoscope115, 1402–1410 (2005).
   PubMedGoogle Scholar
• Sessions DG, Lenox J, Spector GJ et al. Management of T3N0M0 glottic carcinoma: therapeutic outcomes. Laryngoscope112, 1281–1288 (2002).
   PubMed Web of Science ®Google Scholar
• Spector GJ, Sessions DG, Lenox J et al. Management of stage IV glottic carcinoma: therapeutic outcomes. Laryngoscope114, 1438–1446 (2004).
   PubMed Web of Science ®Google Scholar
• Porceddu SV, Jarmolowski E, Hicks RJ et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck27, 175–181 (2005).
   PubMed Web of Science ®Google Scholar
• Greven KM, Williams DW, McGuirt F et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck23, 942–946 (2001).
   PubMed Web of Science ®Google Scholar
• Lapela M, Eigtved A, Jyrkkio S et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur. J. Cancer36, 858–867 (2000).
   PubMedGoogle Scholar
• McCollum AD, Burrell SC, Haddad RI et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck26(10), 890–896 (2004).
   PubMed Web of Science ®Google Scholar
• Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.23, 457–467 (1992).
   PubMed Web of Science ®Google Scholar
• Fu KK, Pajak TF, Trotti A et al. A Radiation Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys.48(1), 7–16 (2000).
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of the head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet362(9388), 933–940 (2003).
   PubMed Web of Science ®Google Scholar
• Horiot JC, LeFur R, N’guyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol.25(4), 231–241 (1992).
   PubMed Web of Science ®Google Scholar
• Horiot JC, Bontemps P, van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother. Oncol.44(2), 111–121 (1997).
   PubMed Web of Science ®Google Scholar
• Bourhis J, Overgaard J Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet368, 843–854 (2006).
   PubMed Web of Science ®Google Scholar
• Kies M, Lewin J, Diaz E et al. Definitive treatment of intermediate stage laryngeal squamous cell cancer (SCC/L) with chemotherapy (CT). Proc. Am. Soc. Clin. Oncol.22(S14), 5533 (2004).
   Google Scholar
• Forastiere AA, Ang K, Brizel D et al. Head and neck cancers. J. Natl Compr. Canc. Netw.3, 316–391 (2005).
   PubMedGoogle Scholar
• Yao M, Dornfeld K, Buatti J et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma – the University of Iowa experience. Int. J. Rad. Biol. Phys.63(2), 410–421 (2005).
   PubMedGoogle Scholar
• Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small lung cancer. J. Clin. Oncol.17(9), 2692–2699 (1999).
   PubMed Web of Science ®Google Scholar
• Carew JF, Shah JP. Advances in multimodality therapy for laryngeal cancer. CA Cancer J. Clin.48, 211–228 (1998).
   PubMedGoogle Scholar
• Hong WK, Schaefer S, Issell B et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer52, 206–210 (1983).
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol.10, 257–263 (1992).
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CARBO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol.5, 521–526 (1994).
   PubMed Web of Science ®Google Scholar
• Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer60, 301–311 (1987).
   PubMed Web of Science ®Google Scholar
• Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program. J. Clin. Oncol.8, 838–847 (1990).
   PubMed Web of Science ®Google Scholar
• Laramore G, Scott C, al-Sarraf M et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int. J. Rad. Oncol. Biol. Phys.23, 705–713 (1992).
   PubMed Web of Science ®Google Scholar
• Pignon J, Bourhis J, Domenge C et al. Chemotherapy added to local-regional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet355, 949 (2000).
   PubMed Web of Science ®Google Scholar
• Merlano M, Benasso M, Corvo R. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J. Natl Cancer Inst.88, 583–589 (1996).
   PubMedGoogle Scholar
• Adelstein D, Li Y, Adams G et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol.21, 92–98 (2003).
   PubMed Web of Science ®Google Scholar
• Adelstein D, Saxton J, Lavertu P et al. A Phase III trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck19, 567–575 (1997).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Lavertu P, Saxton J et al. Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer88(4), 876–883 (2000).
   PubMed Web of Science ®Google Scholar
• Munro A. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br. J. Cancer71, 83–91 (1995).
   PubMed Web of Science ®Google Scholar
• El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective randomized trials. J. Clin. Oncol.14, 838–847 (1996).
   PubMed Web of Science ®Google Scholar
• Wendt T, Grabenbauer G, Rodel C et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized study. J. Clin. Oncol.16, 1318–1324 (1998).
   PubMed Web of Science ®Google Scholar
• Brizel D, Albers M, Fisher S et al. Hyperfractionated irradiation with or without chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med.338, 1798–1804 (1997).
   Google Scholar
• Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol.18, 3320–3321 (2000).
   PubMedGoogle Scholar
• Forastiere A, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med.349, 2091–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Maor M, Weber RS et al. Long-term results of Intergroup RTOG 91-11: a Phase III trial to preserve the larynx – induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J. Clin. Oncol.24(Suppl. 18), 5517 (2006).
   Google Scholar
• Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med.350, 1945–1952 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper J, Pajak T, Forastiere A et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N. Engl. J. Med.350, 1937–1944 (2004).
   PubMed Web of Science ®Google Scholar
• Dropkin M, Malgady RG, Scott DW, Oberst M, Strong EW. Scaling of disfigurement and dysfunction in postoperative head and neck patients. Head Neck Surg.8, 559–570 (1983).
   Google Scholar
• DeSanto LW, Olsen KD, Perry WC, Rohe DE, Keith RL. Quality of life after surgical treatment of cancer of the larynx. Ann. Otol. Rhinol. Laryngol.104, 763–769 (1995).
   PubMed Web of Science ®Google Scholar
• Pfister D, Harrison LB, Strong EW, Bosl GJ. Current status of larynx preservation with multimodality therapy. Oncology6, 33–43 (1992).
   PubMedGoogle Scholar
• Miller S. The role of the speech–language pathologist in voice-restoration after total laryngectomy. CA Cancer J. Clin.40, 174–182 (1990).
   PubMedGoogle Scholar
• McNeil B, Weichselbaum R, Pauker SG. Speech and survival. N. Engl. J. Med.305, 982–987 (1981).
   PubMed Web of Science ®Google Scholar
• The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med.324, 1685–1690 (1991).
   PubMed Web of Science ®Google Scholar
• Terrell J, Fisher S, Wolf G et al. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch. Otolaryngol. Head Neck Surg.124, 964–971 (1998).
   PubMedGoogle Scholar
• Wolf G, Hong W, Fisher S et al. Larynx preservation with induction chemotherapy and radiation in advanced laryngeal cancer: final results of the VA laryngeal cancer study group cooperative trial. Proc. Am. Soc. Clin. Oncol.12, 277 (1993) (Abstract 892).
   Google Scholar
• Lefebvre J, Chevalier D, Luboinski B et al. Larynx preservation in pyeariform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. J. Natl Cancer Inst.88, 890–899 (1996).
   PubMed Web of Science ®Google Scholar
• Richard J, Sancho-Garnier H, Pessey J et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol.34, 224–228 (1998).
   PubMed Web of Science ®Google Scholar
• Lefebvre J, Wolf G, Luboinski B et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (2) larynx preservation using neoadjuvant chemotherapy (CT) in laryngeal and hypopharyngeal carcinoma. Proc. Am. Soc. Clin. Oncol.17, 382 (1998).
   Google Scholar
• Davis GE, Schwartz SR, Veenstra DL et al. Cost comparison of surgery vs organ preservation for laryngeal cancer.Arch. Otolaryngol. Head Neck Surg.131, 21–26 (2005).
   PubMedGoogle Scholar
• Bradford CR, Wolf GT, Carey TE et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol. Head Neck Surg.121(5), 534–538 (1999).
   PubMedGoogle Scholar
• Teknos TN, Cox C, Barrios MA et al. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope112(5), 844–851 (2002).
   PubMedGoogle Scholar
• Urba S, Wolf G, Eisbruch A et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J. Clin. Oncol.24(4), 593–598 (2006).
   PubMed Web of Science ®Google Scholar
• Calais G, Pointreau Y, Alfonsi M et al. Randomized Phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. J. Clin. Oncol.24(Suppl. 18), 5506 (2004).
   Google Scholar
• Zhang X, Choe MS, Lee JE et al. GRIM-19 expression and its correlation with clinical outcomes of an induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol.23(Suppl. 16), 5519 (2005).
   Google Scholar
• Hitt R, Ciruelos E, Amador ML et al. Prognostic value of the epidermal growth factor receptor (EGFR) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur. J. Cancer41(3), 453–460 (2005).
   PubMed Web of Science ®Google Scholar
• Dassonville O, Formento J, Francoual M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol.11, 1873–1878 (1993).
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N et al.In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res.5, 701–708 (2000).
   Google Scholar
• Bonner J, Harari P, Giralt J et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a Phase III study of high dose radiation therapy with or without cetuximab. Proc. Am. Soc. Clin. Oncol.22(Suppl. 14), 5507 (2004).
   Web of Science ®Google Scholar
• Pfister D, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol.24(7), 1072–1078 (2006).
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol.23(34), 8646–8654 (2005).
   PubMed Web of Science ®Google Scholar
• Neuchrist C, Quint C, Pammer A et al. Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study. Acta Otolaryngol.119(6), 732–738 (1999).
   PubMed Web of Science ®Google Scholar
• Onesto C, Hannoun-Levi JM, Chamorey E et al. Vascular endothelial growth factor-A and poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. Br. J. Cancer94(10), 1516–1523 (2006).
   PubMedGoogle Scholar
• Teknos TN, Cox C, Yoo S et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck24(11), 1004–1011 (2002).
   PubMed Web of Science ®Google Scholar
• Homer JJ, Greenman J, Stafford ND. The expression of vascular endothelial growth factor (VEGF) and VEGF-C in early laryngeal cancer: relationship with radioresistance. Clin. Otolaryngol. Allied Sci.26(6), 498–504 (2001).
   PubMedGoogle Scholar
• Hoang T, Huang S, Armstrong E et al. Augmentation of radiation response with the vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys.64(5), 1458–1465 (2006).
   PubMedGoogle Scholar
• Vokes EE, Cohen EW, Mauer AM et al. A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J. Clin. Oncol.23(Suppl. 16), 5504 (2005).
   Google Scholar
• Williamson SK, Moon J, Huang CH et al. A Phase II trial of BAY-43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. Proc. Am. Soc. Clin. Oncol.24(Suppl. 18, Pt 1), 5550 (2006).
   Google Scholar
• Krecicki T, Jelen M, Zalesska-Krecicka M. C-erbB-2 immunostaining in laryngeal cancer. Acta Otolaryngol.119(3), 392–395 (1999).
   PubMedGoogle Scholar
• Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyearosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol.23(23), 5305–5313 (2005).
   PubMed Web of Science ®Google Scholar
• Abidoye OO, Cohen EE, Wong SJ et al. A Phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol.24(Suppl. 18), 5568 (2006).
   Google Scholar
• Arisi E, Pruneri G, Carboni N et al. Prognostic significance of P27 and cyclin D1 co-expression in laryngeal squamous cell carcinoma: possible target for novel therapeutic strategies. J. Chemother. (Suppl. 5), 3–6 (2004).
   PubMedGoogle Scholar
• Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit. Rev. Oncol. Hematol.1, 323–355 (1984).
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Hornedo J, Silva H et al. Carboplatin (NSC-241–240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol.4(10), 1506–1509 (1986).
   PubMed Web of Science ®Google Scholar
• Vermorken J, Bourhis J, Trigo J et al. Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. J. Clin. Oncol.23(S501), 5505 (2005).
   Google Scholar
• Wittes RE. Chemotherapy of head and neck cancer. Otolaryngol. Clin. North Am.13, 515–520 (1980).
   PubMedGoogle Scholar
• Couteau C, Chouaki N, Leyvraz S et al. A Phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer81, 457–462 (1999).
   PubMed Web of Science ®Google Scholar
• Catimel G, Verweij J, Mattijssen V et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck – EORTC Early Clinical Trials Group. Ann. Oncol.5, 533–537 (1994).
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Norris CM et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol.14, 1672–1678 (1996).
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer N, Vokes E et al. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.J. Clin. Oncol.1, 77–85 (2004).
   Google Scholar
• Gedlicka C, Kornfehl J, Turhani D et al. Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer Invest.24(3), 242–245 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.21, 1980–1987 (2003).
   PubMed Web of Science ®Google Scholar
• Kane M, Cohen E, List M et al. Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol.22(Suppl. 14), (2004).
   Google Scholar
• Wheeler RH, Jones D, Sharma P et al. Clinical and molecular Phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J. Clin. Oncol.23(Suppl. 16), 5531 (2005).
   Web of Science ®Google Scholar
• Catimel G, Vermorken JB, Clavel M et al. A Phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck: EORTC Early Clinical Trials Group. Ann. Oncol.5, 543–547 (1994).
   PubMed Web of Science ®Google Scholar
• Airoldi M, Cortesina G, Giordano C et al. Ifosfamide in the treatment of head and neck cancer. Oncology65(Suppl.), 237–243 (2003).
   Google Scholar
• Degardin M, Cappelaere P, Krakowski I et al. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur. J. Cancer B Oral Oncol.32B, 278–279 (1996).
   PubMedGoogle Scholar
• Langer CJ, Li Y, Jennings T et al. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest.22, 823–831 (2004).
   Google Scholar
• Forastiere AA, Shank D, Neuberg D et al. Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer82, 2270–2274 (1998).
   PubMed Web of Science ®Google Scholar
• Pivot X, Raymond E, Laguerre B et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer85, 649–655 (2001).
   PubMed Web of Science ®Google Scholar
• Colevas AD, Amrein PC, Gomolin H et al. A Phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer92(2), 326–331 (2001).
   PubMedGoogle Scholar
• Glick JH, Zehngebot LM, Taylor SG IV. Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. Am. J. Otolaryngol.1, 306–323 (1980).
   PubMedGoogle Scholar
• Testolin A, Recher G, Cristoferi V et al. Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma: a Phase II study. Invest. New Drugs12, 231–234 (1994).
   PubMed Web of Science ®Google Scholar
• Ervin T, Clark J, Weichselbaum R et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol.5, 10–20 (1987).
   PubMed Web of Science ®Google Scholar
• Depondt J, Gehanno P, Martin M et al. Neoadjuvant chemotherapy with carboplatin/5-FU in head and neck cancer. Oncology50(Suppl. 2), 23–27 (1993).
   PubMed Web of Science ®Google Scholar
• Schuller DE, Metch B, Stein DW et al. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope98(11), 1205–1211 (1988).
   PubMed Web of Science ®Google Scholar
• Dalley D, Beller E, Aroney R et al. The value of chemotherapy (CT) prior to definitive local therapy (DLT) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN). Proc. Am. Soc. Clin. Oncol.14, 297 (1995).
   Google Scholar
• Domenge C, Marandas P, Vignoud J et al. Post-surgical adjuvant chemotherapy in extra-capsular spread invaded node (N+R+) of epidermoid carcinoma of the head and neck. A randomized multicentric trial. Second International Conference in Head and Neck, Boston, 1988. Am. Soc. Head Neck Surg. (1988) (Abstract 74).
   Google Scholar
• Rentschler RE, Wilbur DW, Petti GH et al. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas – a prospective, randomized study. J. Clin. Oncol.5(2), 278–285 (1987).
   PubMed Web of Science ®Google Scholar
• Taylor SG, Applebaum E, Showel JL et al. A randomized trial of adjuvant chemotherapy in head and neck cancer. J. Clin. Oncol.3(5), 672–679 (1985).
   PubMed Web of Science ®Google Scholar
• Kun LE, Toohill RJ, Holoye PJ et al. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int. J. Radiat. Oncol. Biol. Phys.12(2), 173–178 (1986).
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Inuyama Y, Miyake H; and the Head and Neck UFT Study Group. Efficacy of surgical adjuvant with tegafur and uracil (UFT) in resectable head and neck cancer: a prospective randomized study. Proc. Am. Soc. Clin. Oncol.13, 284 (1994).
   Google Scholar
• Holoye PY, Grossman TW, Toohill RJ et al. Randomized study of adjuvant chemotherapy for head and neck cancer. Otolaryngol. Head Neck Surg.93(6), 712–717 (1985).
   PubMed Web of Science ®Google Scholar
• Keane T, Cummings B, O’Sullivan B et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin-C and 5-fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int. J. Rad. Oncol. Biol. Phys.25, 613–618 (1993).
   PubMed Web of Science ®Google Scholar
• Sanchiz F, Milla A, Torner J et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys.19(6), 1347–1350 (1990).
   PubMed Web of Science ®Google Scholar
• Corvo R, Benasso M, Sanguineti G et al. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Cancer92(11), 2856–2867 (2001).
   PubMedGoogle Scholar
• A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Cooperative Oncology Group. Eur. J. Surg. Oncol.12, 289–295 (1986).
   PubMedGoogle Scholar
• Adelstein D, Sharan V, Earle A et al. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer65, 1685–1691 (1990).
   PubMed Web of Science ®Google Scholar
• Merlano M, Rosso R, Sertoli M et al. Randomized comparison of two chemotherapy, radiotherapy schemes for stage III and IV unresectable squamous cell carcinoma of the head and neck. Laryngoscope100, 531–535 (1990).
   PubMedGoogle Scholar
• Taylor SJ, Murthy A, Vannetzel J et al. Randomized comparison of neoadjuvant cisplatin and FU infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J. Clin Oncol.12, 385–395 (1994).
   PubMed Web of Science ®Google Scholar
• Bachaud J, Cohen-Jonathan E, Alzieu C et al. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int. J. Rad. Oncol. Biol. Phys.36, 999–1004 (1996).
   PubMed Web of Science ®Google Scholar
• Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.J. Clin. Oncol.23(34), 8636–8645 (2005).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for noresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a Phase III trial of the EORTC Head and Neck Cancer Group (EORTC 24971). J. Clin. Oncol.22(Suppl. 14), 5508 (2004).
   Google Scholar
• Remenar E, Van Herpen C, Germa Lluch J et al. A randomized Phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971. J. Clin. Oncol.24(Suppl. 18), 5516 (2004).
   Google Scholar
• Posner MR, Hershock D, LeLann L et al. A Phase III multicenter trial of docetaxel, cisplatin, and 5-fluorouracil versus cisplatin plus 5-fluorouracil induction chemotherapy followed by chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. Special Scientific Session 24(31), 4991–4997 (2006).
   PubMedGoogle Scholar
• Hitt R, Grau J, Lopez-Pousa A et al. Randomized Phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin /5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs CRT alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J. Clin. Oncol.24(Suppl. 18), 5515 (2004).
   Google Scholar